Drug Profile
Osteopontin - Merck Serono
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck Serono
- Class Cytokines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 05 Jan 2007 Serono has been acquired by Merck KGaA
- 22 Sep 2003 Preclinical trials in Neurological disorders in Switzerland (unspecified route)